Extracorporeal Perfusion of the Tumor Bearing Human Kidney Using Tumor-Specific Monoclonal Antibodies: A Therapeutic Model

Abstract

The use of monoclonal antibodies for tumor specific in vitro diagnosis is well established. With the possibility of producing tumor specific monoclonal antibodies, not only the in vitro application but also the in vivo use for tumor imaging is of great interest (Bander 1984; Mitchell and Oettgen 1982; Moon et al. 1983; Ritz et al. 1981). Methodology for radiolabelling of immunoglobulines is a well established and simple biochemical procedure thus making these antibodies ideal for immuno-szintigraphy (Greenwood et al. 1963; Hunter and Greenwood 1962; Mach et al. 1981; Scheinberg et al. 1982; Solter et al. 1982). Using alpha- or beta-emitting isotopes the therapeutic use of antibodies as tumor-targetted vehicles is feasible. With advances in biochemical conjugation procedures the coupling of cytotoxic drugs or cell toxines is now possible making the tumor specific antibody an ideal carrier for tumor specific application of drugs (Herlyn et al. 1980; Herlyn and Koprowski 1981; Houston and Nowinski 1981; Jansen et al. 1981; Krolik et al. 1983). Unfortunately presently only murine monoclonal antibodies are being produced which may cause problems in vivo being an alien proteine. A number of suggestions were made as how to circumvent the allergic complications possible after application of animal proteins (Baldwin et al. 1985; Craso and Griffin 1981; Gilliand et al. 1980). For the evaluation of our antibodies as possible carriers for radionuclides or cytotoxic drugs to the kidney tumor we developed an extracorporeal therapy model using the tumor bearing vital kidney.